Citation Tools
Ovarian cancer
2022-RA-439-ESGO Up-next (ENGOT-Ov71-NSGO-CTU/GOG-3049): a study of upitifamab rilsodotin (UpRi), a napi2b-directed antibody drug conjugate (ADC) in platinum-sensitive recurrent ovarian cancer
Download to a citation manager
Download the citation for this article by clicking on one of the following citation managers:
- Cite this article as:
- 2022-RA-439-ESGO Up-next (ENGOT-Ov71-NSGO-CTU/GOG-3049): a study of upitifamab rilsodotin (UpRi), a napi2b-directed antibody drug conjugate (ADC) in platinum-sensitive recurrent ovarian cancer